NOVARTIS logo.jpg
Novartis: a enregistré, en 2021, une croissance du chiffre d’affaires net à un chiffre dans le milieu de la fourchette, une expansion de la marge et une avancée du robuste pipeline
February 02, 2022 01:00 ET | Novartis Pharma AG
Annonce événementielle selon l’art. 53 RC Chiffre d’affaires net du 4e trimestre en hausse de +6% (tcc1, +4% USD) et résultat opérationnel core croissant de +12% (tcc1, +9% USD) Innovative...
NOVARTIS logo.jpg
Novartis erzielt 2021 ein Umsatzwachstum im mittleren einstelligen Bereich, verbessert die Margen und treibt die solide Pipeline voran
February 02, 2022 01:00 ET | Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KR Im vierten Quartal stieg der Umsatz um +6% (kWk1, +4% USD), das operative Kernergebnis wuchs um +12% (kWk, +9% USD) Innovative Medicines steigerte den Umsatz um...
NOVARTIS logo.jpg
Novartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021
February 02, 2022 01:00 ET | Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Q4 sales grew +6% (cc1, +4% USD) and core operating income grew +12% (cc, +9% USD) IM sales grew +7% (cc, +5% USD) and core operating income +15% (cc, +12%...
NOVARTIS logo.jpg
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
January 10, 2022 01:15 ET | Novartis Pharma AG
Topline results from the randomized EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo,...
NOVARTIS logo.jpg
Novartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis
December 22, 2021 18:00 ET | Novartis Pharma AG
New approvals are based on JUNIPERA trial data showing Cosentyx® (secukinumab) demonstrated reduced flare risk versus placebo and improvement in disease activity observed over two years across both...
NOVARTIS logo.jpg
FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year
December 22, 2021 16:05 ET | Novartis Pharma AG
  Ad hoc announcement pursuant to Art. 53 LR With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol)...
NOVARTIS logo.jpg
Novartis strengthens immunotherapy pipeline with option, collaboration and license agreement with BeiGene for TIGIT inhibitor ociperlimab
December 20, 2021 06:15 ET | Novartis Pharma AG
Ociperlimab adds innovative and complementary late-stage TIGIT inhibitor to an Oncology portfolio poised for growth Two Phase III trials underway in non-small cell lung cancer and additional studies...
NOVARTIS logo.jpg
Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU)
December 20, 2021 01:15 ET | Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Ligelizumab, a high-affinity anti-IgE antibody, demonstrated superiority compared with placebo at Week 12 in Phase III PEARL 1 and PEARL...
NOVARTIS logo.jpg
Novartis initiates new USD 15 billion share buyback highlighting confidence in growth and pipeline
December 16, 2021 01:00 ET | Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Share buyback of up to USD 15bn planned to be executed by end 2023, highlighting confidence in top line growth and deep pipelineSales expected to grow...
NOVARTIS logo.jpg
Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021
December 13, 2021 14:45 ET | Novartis Pharma AG
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as foundation for various investigational CAR-T therapies Early data from first-in-human dose-escalation...